Contract Development and Manufacturing Organization (CDMO) Market: Focus on Service, Product Type, Application, End User, and Region - Analysis and Forecast, 2026-2036

The global contract development and manufacturing organization (CDMO) market, initially valued at $249.8 billion in 2025, is projected to grow substantially, reaching $593.1 billion by 2036, with a compound annual growth rate (CAGR) of 8.26% from 2026 to 2036.

The global contract development and manufacturing organization (CDMO) market has been experiencing steady growth, driven by increasing outsourcing across pharmaceutical, biotechnology, medical-device, and life-science value chains. CDMOs provide outsourced product development, process optimization, analytical testing, clinical and commercial manufacturing, sterile fill-finish, component manufacturing, device assembly, finished-product manufacturing, and packaging services. The market is supported by expanding pharmaceutical and biologics pipelines, rising product complexity, growing demand for specialized manufacturing capacity, shorter development timelines, and companies’ efforts to reduce capital investment in internal facilities. Pharmaceutical CDMO services represent the largest service segment, reflecting sustained demand for formulation and process development, analytical testing, clinical-scale manufacturing, commercial-scale production, sterile fill-finish, and pharmaceutical packaging. Medical-device CDMO services are gaining importance as original equipment manufacturers increasingly outsource product design, engineering, prototyping, component production, assembly, integration, testing, validation, and finished-device manufacturing. The market also covers contract development and manufacturing of life-science tools and research-use products.

Market Introduction

The global contract development and manufacturing organization (CDMO) market represents third-party service providers offering outsourced development and manufacturing services to pharmaceutical, biotechnology, medical-device, and life-science companies. The market includes revenues generated from contract development, process optimization, analytical testing, clinical and commercial manufacturing, sterile fill-finish, component production, device assembly, finished-product manufacturing, and packaging across the product lifecycle.

The market has evolved significantly as outsourcing relationships have shifted from transactional manufacturing arrangements toward strategic and integrated development-to-commercialization partnerships. Pharmaceutical and biotechnology companies use CDMOs to access formulation, process development, analytical, biologics manufacturing, high-potency synthesis, advanced-therapy, and sterile-processing capabilities. Medical-device companies use CDMOs for product engineering, design transfer, prototyping, precision manufacturing, electronics integration, cleanroom assembly, testing, validation, and commercial-scale production.

The market is increasingly shaped by integrated end-to-end service platforms, longer-term contracts, dual-sourced regional manufacturing networks, modular facilities, single-use technologies, automation, process analytical technology, artificial intelligence, digital twins, and advanced manufacturing systems. These capabilities allow CDMOs to improve technology transfer, manufacturing flexibility, supply continuity, batch monitoring, quality control, and operational efficiency across multiple sites.

Companies operating in the market are focusing on technical expertise, regulatory compliance, manufacturing scale, capacity utilization, geographic reach, supply-chain resilience, speed of technology transfer, and the ability to support products from early development through commercial production. As pharmaceutical, biotechnology, and medical-device companies continue to prioritize asset-light operating models, specialized and integrated CDMOs are expected to become increasingly important across global healthcare and life-science supply chains.

Industrial Impact

The global contract development and manufacturing organization (CDMO) market has witnessed increasing adoption, driven by the need for specialized development expertise, flexible production capacity, regulatory-compliant manufacturing, and faster commercialization across pharmaceutical and medical-device industries. Key players such as Lonza, Thermo Fisher Scientific Inc., Catalent, Inc., Samsung Biologics, Boehringer Ingelheim International GmbH, Recipharm AB, Siegfried Holding AG, Piramal Pharma Limited, CordenPharma, AGC Inc., Molex, Integer Holdings Corporation, Jabil Inc., Sanmina Corporation, and Quasar Medical play an important role in advancing outsourced development and manufacturing capabilities.

These companies support small molecules, biologics, sterile products, vaccines, peptides, oligonucleotides, antibody-drug conjugates, cell and gene therapies, surgical and interventional devices, implants, in vitro diagnostic devices, drug-delivery systems, patient-monitoring devices, and life-science research products. By providing integrated development, technology transfer, manufacturing, testing, assembly, fill-finish, and packaging services, CDMOs enable product companies to reduce capital requirements, access specialized infrastructure, improve production flexibility, and accelerate the transition from clinical development to commercial supply.

The market’s impact is most visible among pharmaceutical and biotechnology companies with expanding pipelines but limited specialized manufacturing capacity. Medical-device companies also increasingly rely on CDMOs for precision components, complex assemblies, electronics integration, cleanroom production, and finished-device manufacturing. However, regulatory remediation, quality-system failures, capacity-demand imbalances, sponsor funding constraints, supply-chain disruptions, and high fixed operating costs continue to affect utilization and commercial performance.

Market Segmentation:

Segmentation 1: By Service

• Pharmaceutical CDMO Services
• Medical Device CDMO Services

Pharmaceutical CDMO Services Segment to Dominate the Contract Development and Manufacturing Organization (CDMO) Market (by Service)

In 2025, pharmaceutical CDMO services accounted for the largest market share due to sustained outsourcing across formulation development, process development, analytical testing, clinical manufacturing, commercial-scale production, sterile fill-finish, and pharmaceutical packaging. The segment is supported by expanding small-molecule and biologics pipelines, increasing demand for specialized manufacturing capacity, and pharmaceutical and biotechnology companies’ efforts to reduce capital expenditure and improve development flexibility. Medical-device CDMO services are expected to register the highest growth, supported by increasing outsourcing of product engineering, prototyping, component manufacturing, device assembly, testing, and finished-device production.

Segmentation 2: By Product Type

• Pharmaceuticals
• Small Molecules
• Biologics
• Medical Devices
• Surgical and Interventional Devices
• Implantable Medical Devices
• In Vitro Diagnostic Devices
• Drug Delivery Devices
• Patient Monitoring and Diagnostic Devices
• Others

Small Molecules Segment to Dominate the Contract Development and Manufacturing Organization (CDMO) Market, Pharmaceuticals (by Product Type)

In 2025, pharmaceuticals accounted for the largest product-type share, supported by extensive outsourcing of drug development, clinical manufacturing, commercial production, sterile fill-finish, and packaging. Within pharmaceuticals, small molecules represented the largest segment due to their established role in approved therapies, extensive development pipelines, mature manufacturing infrastructure, and broad demand for active pharmaceutical ingredients, intermediates, and finished dosage forms. Biologics are expected to register faster growth, supported by increasing development of monoclonal antibodies, recombinant proteins, vaccines, biosimilars, antibody-drug conjugates, and cell and gene therapies.

Segmentation 3: By Application

• Pharmaceuticals
• Oncology
• Infectious Disease
• Cardiovascular Diseases
• Neurology
• Metabolic Disorders
• Immunology
• Rare Diseases
• Others
• Medical Devices
• Cardiovascular
• Orthopedics
• Diabetes
• Neurology
• Gastroenterology
• Oncology
• Ophthalmology
• Others
• Others Application

Oncology Segment to Dominate the Contract Development and Manufacturing Organization (CDMO) Market, Pharmaceuticals (by Application)

In 2025, oncology accounted for the largest share of the pharmaceutical application segment due to the expanding oncology drug pipeline, increasing development of targeted therapies and biologics, and strong demand for specialized clinical and commercial manufacturing capabilities. Oncology is also expected to register the highest growth during the forecast period, supported by increasing investment in cancer research, personalized therapies, antibody-drug conjugates, high-potency compounds, biologics, and complex sterile products. Medical-device applications span cardiovascular care, orthopedics, diabetes, neurology, gastroenterology, oncology, ophthalmology, and other therapeutic areas.

Segmentation 4: By End User

• Academic and Research Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Medical Device Companies
• Other End Users

Pharmaceutical Companies to Dominate the Contract Development and Manufacturing Organization (CDMO) Market (by End User)

In terms of end user, pharmaceutical companies are expected to lead the global Contract Development and Manufacturing Organization (CDMO) market. These companies extensively use CDMOs for small-molecule and biologics development, formulation, process optimization, analytical testing, clinical manufacturing, commercial-scale production, sterile fill-finish, packaging, and lifecycle support. Outsourcing allows pharmaceutical companies to access specialized capabilities, manage capacity fluctuations, establish secondary supply sources, reduce fixed manufacturing expenditure, and accelerate product launches. Biotechnology companies are expected to register the highest growth due to expanding biologics and advanced-therapy pipelines and their comparatively limited internal manufacturing infrastructure.

Segmentation 5: By Region

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Rest-of-Europe
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest-of-Asia-Pacific
• Latin America
• Brazil
• Mexico
• Rest-of-Latin America
• Middle East and Africa
• K.S.A.
• Egypt
• Rest-of-Middle East and Africa

North America to Dominate the Contract Development and Manufacturing Organization (CDMO) Market (by Region)

In terms of region, North America is expected to lead the global Contract Development and Manufacturing Organization (CDMO) market, supported by its well-established pharmaceutical, biotechnology, medical-device, and life-science industries, advanced manufacturing infrastructure, high level of outsourcing, and strong presence of global CDMO companies. The U.S. represents the largest country-level market due to its extensive drug-development pipeline, concentration of pharmaceutical and medical-device companies, advanced biologics and sterile-manufacturing capabilities, and established regulatory and quality infrastructure.

The region’s growth is also supported by investments in domestic manufacturing, supply-chain resilience, advanced therapies, biologics, sterile fill-finish, and medical-device production. Asia-Pacific is expected to register the highest growth during the forecast period due to expanding pharmaceutical and medical-device manufacturing capacity, cost-competitive production, investment in biologics and advanced technologies, and the increasing presence of regional and international CDMOs across China, India, Japan, South Korea, Australia, and other regional markets.

Recent Developments in the Contract Development and Manufacturing Organization (CDMO) Market

• In June 2026, AGC Inc. announced an integrated U.S. offering combining biologics drug-substance manufacturing with sterile fill-finish services. The offering supports liquid and lyophilized vials, prefilled syringes, cartridges, device assembly, labeling, and secondary packaging.
• In July 2026, Lonza entered multiple customer licensing agreements covering its linker-payload and bioconjugation technologies. The agreements expanded customer access to its antibody-drug conjugate development platform for single-target, multi-target, and dual-payload therapeutic programs.
• In April 2026, Quasar Medical opened an additional manufacturing facility in Chonburi, Thailand. The facility expanded capacity for catheter systems, balloon technologies, micro-sensor products, complex assemblies, and finished medical devices while strengthening its geographic manufacturing network.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Commercial Biologics Volumes and Late-Stage Progression Sustaining Drug-Substance, Analytical Testing, and Sterile Fill-Finish Orders: The expanding commercial base of monoclonal antibodies, recombinant proteins, vaccines, biosimilars, and other large-molecule therapies is generating recurring demand for CDMO services. As biologics advance into late-stage clinical development, process-performance qualification, regulatory approval, and commercial supply, sponsors require validated cell-culture and purification processes, comparability studies, analytical testing, stability programs, clinical and commercial drug-substance manufacturing, sterile fill-finish, and packaging. Increasing product approvals, indication expansion, geographic launches, and additional dosage presentations are expected to sustain long-term manufacturing and testing contracts.

Market Challenges

Quality-System Failures and Regulatory Remediation Interrupting Batch Release and Deferring CDMO Revenue: Quality-system failures remain a major challenge for the CDMO market because revenue depends on both manufacturing output and complete evidence that facilities, processes, equipment, personnel, and products meet applicable regulatory standards. Deficiencies in contamination control, investigations, equipment qualification, environmental monitoring, data integrity, or manufacturing records can place batches on hold, delay release, require repeat production, and prevent facilities from accepting new projects. Remediation can consume manufacturing capacity, increase testing and consulting expenses, delay milestone payments, and cause customers to transfer future projects to alternative suppliers.

Market Opportunities

Advanced-Therapy Commercialization Could Convert Underutilized Cell, Gene, and Viral-Vector Capacity into Recurring CDMO Revenue: The commercialization of cell therapies, gene therapies, viral-vector products, plasmid DNA, and other advanced therapeutic modalities presents a significant opportunity for the CDMO market. Current advanced-therapy programs generate development and clinical-manufacturing demand, but uneven pipeline progression and product-specific manufacturing processes have resulted in underutilized capacity at certain facilities. As more products progress into process validation, commercial manufacturing, regulatory inspection, and continuing analytical release, CDMOs could generate recurring revenue from vector production, cell processing, analytical development, potency testing, clinical manufacturing, aseptic processing, cryopreservation, batch release, and chain-of-identity management.

How can this report add value to an organization?

Product/Innovation Strategy: The global contract development and manufacturing organization market has been divided into several key segments, including service, product type, application, end user, and regional markets. By understanding demand across pharmaceutical development and manufacturing services, medical-device engineering and manufacturing services, small molecules, biologics, therapeutic and diagnostic devices, and life-science tools, this report offers valuable insights for organizations seeking to refine their service and innovation strategies.

Growth/Marketing Strategy: Increasing pharmaceutical and medical-device outsourcing, expanding biologics and advanced-therapy pipelines, rising demand for sterile fill-finish, growth in high-potency and antibody-drug conjugate programs, medical-device miniaturization, drug-device combination products, regional manufacturing expansion, and supply-chain diversification are anticipated to be central to the growth of the CDMO market. Key developments among pharmaceutical CDMOs, medical-device manufacturers, biotechnology companies, and product sponsors are shaping demand across development, clinical manufacturing, commercial production, and lifecycle support.

Competitive Strategy: The CDMO market is competitive and capability-driven, with large integrated providers and specialized companies competing through service breadth, technical expertise, regulatory compliance, manufacturing scale, geographic footprint, quality performance, technology-transfer speed, supply-chain reliability, and manufacturing flexibility. Key market players are strengthening their positions through acquisitions, strategic partnerships, capacity expansion, digital manufacturing, automation, single-use technologies, modular facilities, and integrated development-to-commercialization offerings.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• Years from 2024 to 2036 have been considered for the global market size estimation; 2025 has been considered as the base year, and 2026 to 2036 as the forecast period.
• The scope of the report is based on comprehensive inputs from industry experts and key stakeholders across the pharmaceutical, biotechnology, medical-device, life-science, and CDMO ecosystem, including contract development and manufacturing organizations, pharmaceutical and biotechnology companies, medical-device companies, raw-material and component suppliers, packaging and sterile fill-finish service providers, analytical testing and quality service providers, and academic and research institutions.
• Revenues from companies have been sourced from their annual reports for FY2024 and FY2025. For private companies, revenue estimates have been derived from primary research inputs, funding history, market collaborations, and operational performance.
• The market has been mapped based on the existing contract development and manufacturing services offered across the pharmaceutical, biotechnology, medical-device, and life-science industries. Key companies with significant pharmaceutical and medical-device development and manufacturing capabilities have been identified and profiled in this report.

Primary Research

The primary sources involve industry experts and key stakeholders across the pharmaceutical, biotechnology, medical-device, and contract development and manufacturing organization ecosystem, including CDMOs, pharmaceutical and biotechnology companies, medical-device companies, raw-material and component suppliers, packaging and fill-finish service providers, and analytical-testing and quality-service providers. Respondents such as CEOs, vice presidents, business-development directors, commercial heads, manufacturing and operations heads, research and development heads, quality and regulatory-affairs leaders, procurement heads, and supply-chain executives have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

• validation and triangulation of all the numbers and graphs
• validation of report segmentations and key qualitative findings
• understanding the competitive landscape and business model
• current and proposed production values of a product by market players
• validation of the numbers of different segments of the market in focus
• percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investors’ presentations of the leading market players
• Company websites and a detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• segmentations and percentage shares
• data for market value
• key industry trends of the top players in the market
• qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Lonza
• Thermo Fisher Scientific Inc.
• Catalent, Inc.
• Samsung Biologics
• Boehringer Ingelheim International GmbH
• Recipharm AB
• Siegfried Holding AG
• Piramal Pharma Limited
• CordenPharma
• AGC Inc.
• Molex
• Integer Holdings Corporation
• Jabil Inc.
• Sanmina Corporation
• Quasar Medical